G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer

Breast Cancer Research and Treatment

Volumn 128, Issue 2, 2011, Pages 457-466

  Ignatov, Atanas ^a   Ignatov, Tanja ^a   Weienborn, Christine ^a   Eggemann, Holm ^a   Bischoff, Joachim ^a   Semczuk, Andrzej ^b   Roessner, Albert ^a   Costa, Serban Dan ^a   Kalinski, Thomas ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Breast cancer; Estrogen receptor; GPR30; Tamoxifen resistance

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; G PROTEIN COUPLED RECEPTOR 30; METHOTREXATE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RESISTANCE; CONTROLLED STUDY; EMBRYO; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MASTECTOMY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELAPSE FREE SURVIVAL; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, G-PROTEIN-COUPLED; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 79959770197     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1584-1     Document Type: Article

References (34)

1. Early Breast Cancer Trialists' Collaborative Group 1998 Tamoxifen for early breast cancer: an overview of the randomised trials Lancet 351 1451 1467 10.1016/S0140-6736(97)11423-4 (Pubitemid 28227036)
2. TJ Powles S Ashley A Tidy IE Smith M Dowsett 2007 Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial J Natl Cancer Inst 99 283 290 17312305 10.1093/jnci/djk050 1:CAS:528:DC%2BD2sXjsVeitrg%3D (Pubitemid 47073491)
3. IR Hutcheson JM Knowlden TA Madden D Barrow JM Gee AE Wakeling RI Nicholson 2003 Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells Breast Cancer Res Treat 81 81 93 14531500 10.1023/A:1025484908380 1:CAS:528:DC%2BD3sXms1Gjs7o%3D (Pubitemid 37108443)
4. A Ignatov T Ignatov A Roessner SD Costa T Kalinski 2009 Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells Breast Cancer Res Treat 123 87 96 19911269 10.1007/s10549-009-0624-6
5. JM Rae MD Johnson 2005 What does an orphan G-protein-coupled receptor have to do with estrogen? Breast Cancer Res 7 243 244 16280047 10.1186/bcr1330 1:CAS:528:DC%2BD2MXht1WmsrrF (Pubitemid 41830160)
6. ER Prossnitz TI Oprea LA Sklar JB Arterburn 2008 The ins and outs of GPR30: a transmembrane estrogen receptor J Steroid Biochem Mol Biol 109 350 353 18406603 10.1016/j.jsbmb.2008.03.006 1:CAS:528:DC%2BD1cXmsVeitb0%3D
7. EJ Filardo JA Quinn KI Bland AR Frackelton Jr. 2000 Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF Mol Endocrinol 14 1649 1660 11043579 10.1210/me.14.10.1649 1:CAS:528:DC%2BD3cXntVaksLk%3D
8. DP Pandey R Lappano L Albanito A Madeo M Maggiolini D Picard 2009 Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF EMBO J 28 523 532 19153601 10.1038/emboj.2008.304
9. P Thomas Y Pang EJ Filardo J Dong 2005 Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells Endocrinology 146 624 632 15539556 10.1210/en.2004-1064 1:CAS:528:DC%2BD2MXotlWitw%3D%3D (Pubitemid 40129818)
10. A Vivacqua D Bonofiglio AG Recchia AM Musti D Picard S Ando M Maggiolini 2006 The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells Mol Endocrinol 20 631 646 16239258 10.1210/me.2005-0280 1:CAS:528: DC%2BD28Xit1Snsb4%3D (Pubitemid 43291214)
11. A Vivacqua D Bonofiglio L Albanito A Madeo V Rago A Carpino AM Musti D Picard S Ando M Maggiolini 2006 17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g protein-coupled receptor GPR30 Mol Pharmacol 70 1414 1423 16835357 10.1124/mol.106.026344 1:CAS:528:DC%2BD28XhtVOjtL7J (Pubitemid 44435994)
12. CK Osborne J Shou S Massarweh R Schiff 2005 Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer Clin Cancer Res 11 865s 870s 15701879 1:CAS:528:DC%2BD2MXislWgu7k%3D (Pubitemid 40111098)
13. T Ignatov H Eggemann A Semczuk B Smith J Bischoff A Roessner SD Costa T Kalinski A Ignatov 2010 Role of GPR30 in endometrial pathology after tamoxifen for breast cancer Am J Obstet Gynecol 203 595 20965484 10.1016/j.ajog.2010.07. 034 e9-e16
14. E Filardo J Quinn Y Pang C Graeber S Shaw J Dong P Thomas 2007 Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane Endocrinology 148 3236 3245 17379646 10.1210/en.2006-1605 1:CAS:528:DC%2BD2sXntVOnsr4%3D (Pubitemid 46997004)
15. L Kang X Zhang Y Xie Y Tu D Wang Z Liu ZY Wang 2010 Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling Mol Endocrinol 24 709 721 20197310 10.1210/me.2009-0317 1:CAS:528:DC%2BC3cXksVOhsbw%3D
16. JM Giltnane L Ryden M Cregger PO Bendahl K Jirstrom DL Rimm 2007 Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer J Clin Oncol 25 3007 3014 17634479 10.1200/JCO.2006.08.9938 (Pubitemid 47218046)
17. JL Hayward PP Carbone JC Heusen S Kumaoka A Segaloff RD Rubens 1977 Assessment of response to therapy in advanced breast cancer Br J Cancer 35 292 298 856236 10.1038/bjc.1977.42 1:STN:280:DyaE2s7lslGquw%3D%3D
18. EJ Filardo CT Graeber JA Quinn MB Resnick D Giri RA DeLellis MM Steinhoff E Sabo 2006 Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression Clin Cancer Res 12 6359 6366 17085646 10.1158/1078-0432.CCR-06-0860 1:CAS:528:DC%2BD28XhtFKitb7M (Pubitemid 44799705)
19. Q Liu JG Li XY Zheng F Jin HT Dong 2009 Expression of CD133, PAX2, ESA, and GPR30 in invasive ductal breast carcinomas Chin Med J (Engl.) 122 2763 2769
20. HO Smith KK Leslie M Singh CR Qualls CM Revankar NE Joste ER Prossnitz 2007 GPR30: a novel indicator of poor survival for endometrial carcinoma Am J Obstet Gynecol 196 386 389 17403429
21. EJ Filardo JA Quinn E Sabo 2008 Association of the membrane estrogen receptor, GPR30, with breast tumor metastasis and transactivation of the epidermal growth factor receptor Steroids 73 870 873 18289622 10.1016/j.steroids.2007.12.025 1:CAS:528:DC%2BD1cXmvFensLs%3D
22. L Albanito D Sisci S Aquila E Brunelli A Vivacqua A Madeo R Lappano DP Pandey D Picard L Mauro S Ando M Maggiolini 2008 Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells Endocrinology 149 3799 3808 18467441 10.1210/en.2008-0117 1:CAS:528:DC%2BD1cXptlamsLk%3D
23. A Vivacqua R Lappano P De Marco D Sisci S Aquila F De Amicis SA Fuqua S Ando M Maggiolini 2009 G Protein-coupled receptor 30 expression is up-regulated by EGF and TGFα in estrogen receptor α-positive cancer cells Mol Endocrinol 23 1815 1826 19749156 10.1210/me.2009-0120 1:CAS:528: DC%2BD1MXhsValsL3E
24. CR King MH Kraus SA Aaronson 1985 Amplification of a novel v-erbB-related gene in a human mammary carcinoma Science 229 974 976 2992089 10.1126/science.2992089 1:CAS:528:DyaL2MXlsFGit7k%3D (Pubitemid 16248488)
25. DJ Slamon GM Clark SG Wong WJ Levin A Ullrich WL McGuire 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177 182 3798106 10.1126/science.3798106 1:CAS:528:DyaL2sXhtVSht7s%3D (Pubitemid 17231334)
26. MJ van de Vijver WJ Mooi P Wisman JL Peterse R Nusse 1988 Immunohistochemical detection of the neu protein in tissue sections of human breast tumors with amplified neu DNA Oncogene 2 175 178 3285295 (Pubitemid 18059001)
27. A Borg B Baldetorp M Ferno D Killander H Olsson S Ryden H Sigurdsson 1994 ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer Cancer Lett 81 137 144 7912163 10.1016/0304-3835(94) 90194-5 1:CAS:528:DyaK2cXkslehtLo%3D (Pubitemid 24184647)
28. MJ Ellis A Coop B Singh L Mauriac A Llombert-Cussac F Janicke WR Miller DB Evans M Dugan C Brady E Quebe-Fehling M Borgs 2001 Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial J Clin Oncol 19 3808 3816 11559718 1:CAS:528:DC%2BD3MXnsVKqsbo%3D (Pubitemid 32880059)
29. SJ Houston TA Plunkett DM Barnes P Smith RD Rubens DW Miles 1999 Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer Br J Cancer 79 1220 1226 10098763 10.1038/sj.bjc.6690196 1:STN:280:DyaK1M7ps1equw%3D%3D (Pubitemid 29087902)
30. AS Knoop SM Bentzen MM Nielsen BB Rasmussen C Rose 2001 Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients J Clin Oncol 19 3376 3384 11454885 1:CAS:528:DC%2BD3MXlvVamsrg%3D (Pubitemid 32642190)
31. I Soubeyran N Quenel L Mauriac M Durand F Bonichon J-M Coindre 1996 Variation of hormonal receptor, pS2, c-erbB-2 and GSTpi contents in breast carcinomas under tamoxifen: a study of 74 cases Br J Cancer 73 735 743 8611373 10.1038/bjc.1996.129 1:CAS:528:DyaK28Xitl2nsL4%3D (Pubitemid 26105299)
32. EA Ariazi E Brailoiu S Yerrum HA Shupp MJ Slifker HE Cunliffe MA Black AL Donato JB Arterburn TI Oprea ER Prossnitz NJ Dun VC Jordan 2010 The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells Cancer Res 70 1184 1194 20086172 10.1158/0008-5472.CAN-09-3068 1:CAS:528:DC%2BC3cXht12rurg%3D
33. WH Kuo LY Chang DL Liu HL Hwa JJ Lin PH Lee CN Chen HC Lien RH Yuan CT Shun KJ Chang FJ Hsieh 2007 The interactions between GPR30 and the major biomarkers in infiltrating ductal carcinoma of the breast in an Asian population Taiwan J Obstet Gynecol 46 135 145 17638621 10.1016/S1028-4559(07)60007-2 (Pubitemid 47236783)
34. ER Levin 2009 G protein-coupled receptor 30: estrogen receptor or collaborator? Endocrinology 150 1563 1565 19307418 10.1210/en.2008-1759 1:CAS:528:DC%2BD1MXktVWmurg%3D